Last reviewed · How we verify
Fluomizin vaginal tablets
Fluomizin vaginal tablets, marketed by Medinova AG, hold a niche position in the treatment of vaginal infections. The key composition patent is set to expire in 2028, providing a period of market exclusivity that supports current revenue streams. The primary risk is the potential for increased competition post-patent expiry, which could erode market share and revenue.
At a glance
| Generic name | Fluomizin vaginal tablets |
|---|---|
| Also known as | 10 mg dequalinium chloride vaginal tablets, Donaxyl vaginal tablets, Naxyl vaginal tablets |
| Sponsor | Medinova AG |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Dequalinium Chloride (Fluomizin) vs Oral Metronidazole for the Treatment of Bacterial Vaginosis (PHASE4)
- Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis (PHASE4)
- Comparative Study of Efficacy of 10 mg Dequalinium Chloride (Fluomizin) in the Local Treatment of Bacterial Vaginosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |